A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder

Nord J Psychiatry. 2015 May;69(4):241-8. doi: 10.3109/08039488.2014.972975. Epub 2014 Nov 21.


Background: No published systematic review has ever assessed the efficacy and safety of reboxetine for treating of patients with attention deficit hyperactivity disorder (ADHD).

Aim: This systematic review aimed to review the available evidence regarding the efficacy of reboxetine for treating ADHD.

Method: The databases of Pubmed/Medline, Google scholar, SCOPUS and Web of Science were searched using the Keywords: "reboxetine", "ADHD" and "attention deficit hyperactivity disorder". The reference lists of the included studies were screened to find any possible other relevant articles. All the non-controlled and controlled clinical trials were included.

Results: The current evidence mainly consists of un-controlled studies, such as case series. Only three of 33 studies were controlled clinical trials. They are from single sites and included a sub-sample of patients with ADHD.

Conclusion: Non-controlled studies and controlled trials support the promising effect of reboxetine for treating ADHD in a sub-sample of patients that are without co-morbid psychiatric disorder and mental retardation. Reboxetine is tolerated well. However, more controlled trials are needed to reach any firm conclusion.

Keywords: Adolescents; Attention deficit hyperactivity disorder; Children; Clinical trial; Reboxetine; Treatment.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Adrenergic Uptake Inhibitors / therapeutic use*
  • Attention Deficit Disorder with Hyperactivity / diagnosis*
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Attention Deficit Disorder with Hyperactivity / psychology
  • Humans
  • Morpholines / therapeutic use*
  • Randomized Controlled Trials as Topic / methods
  • Reboxetine
  • Treatment Outcome


  • Adrenergic Uptake Inhibitors
  • Morpholines
  • Reboxetine